Replies to post #116 on Precision BioSciences Inc (DTIL)

[jondoeuk]

Is NVS picking CD39-CD69- t cells?

No, but the phenotype is naïve and/or stem central memory.

Which alloc CART T in clinical trial is CD39-CD69-?

None that I'm aware of. However, it has been shown (data from auto trials) that product-related T-cell characteristics influence clinical outcome. For example, in R/R CLL the proportion of a specific memory population (CD8+CD27+PD-1-) correlated with complete responses [1], while in R/R LBCL a different population (CD8+CCR7+CD27+) were three times higher in patients who achieved a complete response compared to those who didn't [2].

Based on that they could screen donors for those phenotypes and test different products. In addition, it is possible to remove both exhausted and senescent populations, before and after production.

Refs:
1 https://www.nature.com/articles/s41591-018-0010-1
2 https://www.nature.com/articles/s41591-020-1061-7